Jo El J. Schultz, PHD

Manning, Janet R; Perkins, Sarah O; Sinclair, Elizabeth A; Gao, Xiaoqian; Zhang, Yu; Newman, Gilbert; Pyle, W Glen; Schultz, Jo El J 2013. Low molecular weight fibroblast growth factor-2 signals via protein kinase C and myofibrillar proteins to protect against postischemic cardiac dysfunction. American journal of physiology. Heart and circulatory physiology, 304 10, H1382-96

Wijeratne, Aruna B; Manning, Janet R; Schultz, Jo El J; Greis, Kenneth D 2013. Quantitative phosphoproteomics using acetone-based Peptide labeling: method evaluation and application to a cardiac ischemia/reperfusion model. Journal of proteome research, 12 10, 4268-79

Bolte, Craig; Zhang, Yufang; York, Allen; Kalin, Tanya V; Schultz, Jo El J; Molkentin, Jeffery D; Kalinichenko, Vladimir V 2012. Postnatal ablation of Foxm1 from cardiomyocytes causes late onset cardiac hypertrophy and fibrosis without exacerbating pressure overload-induced cardiac remodeling. PloS one, 7 11, e48713

Manning, Janet R; Carpenter, Gregory; Porter, Darius R; House, Stacey L; Pietras, Daniel A; Doetschman, Thomas; Schultz, Jo el J 2012. Fibroblast growth factor-2-induced cardioprotection against myocardial infarction occurs via the interplay between nitric oxide, protein kinase signaling, and ATP-sensitive potassium channels. Growth factors (Chur, Switzerland), 30 2, 124-39

Schulz, Emily M; Correll, Richard N; Sheikh, Hajer N; Lofrano-Alves, Marco S; Engel, Patti L; Newman, Gilbert; Schultz, Jo El J; Molkentin, Jeffery D; Wolska, Beata M; Solaro, R John; Wieczorek, David F 2012. Tropomyosin dephosphorylation results in compensated cardiac hypertrophy. The Journal of biological chemistry, 287 53, 44478-89

House, Stacey L; House, Brian E; Glascock, Betty; Kimball, Thomas; Nusayr, Eyad; Schultz, Jo El J; Doetschman, Thomas 2010. Fibroblast Growth Factor 2 Mediates Isoproterenol-induced Cardiac Hypertrophy through Activation of the Extracellular Regulated Kinase. Molecular and cellular pharmacology, 2 4, 143-154

Liao, Siyun; Bodmer, Janet R; Azhar, Mohamad; Newman, Gilbert; Coffin, J Douglas; Doetschman, Thomas; Schultz, Jo El J 2010. The influence of FGF2 high molecular weight (HMW) isoforms in the development of cardiac ischemia-reperfusion injury. Journal of molecular and cellular cardiology, 48 6, 1245-54

Bolte, Craig; Newman, Gilbert; Schultz, Jo El J 2009. Kappa and delta opioid receptor signaling is augmented in the failing heart. Journal of molecular and cellular cardiology, 47 4, 493-503

Bolte, Craig; Newman, Gilbert; Schultz, Jo El J 2009. Hypertensive state, independent of hypertrophy, exhibits an attenuated decrease in systolic function on cardiac kappa-opioid receptor stimulation. American journal of physiology. Heart and circulatory physiology, 296 4, H967-75

Jones, W Keith; Fan, Guo-Chang; Liao, Siyun; Zhang, Jun-Ming; Wang, Yang; Weintraub, Neal L; Kranias, Evangelia G; Schultz, Jo El; Lorenz, John; Ren, Xiaoping 2009. Peripheral nociception associated with surgical incision elicits remote nonischemic cardioprotection via neurogenic activation of protein kinase C signaling. Circulation, 120 11 Suppl, S1-9

Flaherty M, Brown M, Grupp I, Schultz J, Murphree S, Jones WK 2007. eNOS deficient mice develop progressive cardiac hypertrophy with altered cytokine and calcium handling protein expression Cardiovasc Tox, 7 3, 165-77

House SL, Melhorn S, Newman G, Doetschman T, Schultz Jel J 2007. Cardiac-specific overexpression of FGF2 is cardioprotective via a protein kinase C-dependent pathway in a murine model of global low-flow ischemia Am J Physiol, 293 1, H354-65

Liao, Siyun; Porter, Darius; Scott, Alana; Newman, Gilbert; Doetschman, Thomas; Schultz, Jo El J 2007. The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: the role of JNK signaling. Journal of molecular and cellular cardiology, 42 1, 106-20

Ji Y, Zhao W, Kaetzel M, Li B, Schultz Jel J, Kranias E, Bers DM, Dedman JR 2006. Targeted inhibition of sarcoplasmic reticulum CaMKII activity results in alterations of Ca2+ homeostasis and cardiac contractility Am J Physiol, 290 2, H599-606

Ji, Yong; Zhao, Wen; Li, Bailing; Desantiago, Jaime; Picht, Eckard; Kaetzel, Marcia A; Schultz, Jo El J; Kranias, Evangelia G; Bers, Donald M; Dedman, John R 2006. Targeted inhibition of sarcoplasmic reticulum CaMKII activity results in alterations of Ca2+ homeostasis and cardiac contractility. American journal of physiology. Heart and circulatory physiology, 290 2, H599-606

Zhao W, Yuan Q, Pathak A, Chu G, Mitton B, Waggoner J, Qian J, Sun X, Jin J, Braz JC, Hahn HS, Marreez Y, Syed F, Pollesello P, Annila A, Brown KM, Wang H, Schultz Jel J, Molkentin JG, Liggett SB, Dorn II GW, Kranias EG 2006. The presence of Lys27 instead of Asn27 in human phospholamban promotes SERCA2 superinhibition and cardiac remodeling Circulation, 113 7, 995-1004

Zhao, Wen; Yuan, Qunying; Qian, Jiang; Waggoner, Jason R; Pathak, Anand; Chu, Guoxiang; Mitton, Bryan; Sun, Xiaoyin; Jin, Jay; Braz, Julian C; Hahn, Harvey S; Marreez, Yehia; Syed, Faisal; Pollesello, Piero; Annila, Arto; Wang, Hong-Sheng; Schultz, Jo El J; Molkentin, Jeffery D; Liggett, Stephen B; Dorn, Gerald W; Kranias, Evangelia G 2006. The presence of Lys27 instead of Asn27 in human phospholamban promotes sarcoplasmic reticulum Ca2+-ATPase superinhibition and cardiac remodeling. Circulation, 113 7, 995-1004

Gumina RJ, El Schultz J, Moore J, Beier N, Schelling P, Gross GJ 2005. Cardioprotective-mimetics reduce myocardial infarct size in animals resistant to ischemic preconditioning Cardiovasc Drugs Ther, 19 5, 315-22

House SL, Branch K, Newman G, Doetschman T, Schultz Jel J 2005. Cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 is mediated by the MAPK cascade Am J Physiol, 289 5, H2167-2175

Pathak A, del Monte F, Zhao W, Schultz JE, Lorenz JN, Bodi I, Weiser D, Hahn H, Carr AN, Syed F, Mavila N, Jha L, Qian J, Mareez Y, Chen G, McGraw DW, Heist EK, Guerrero JL, DePaoli-Roach AA, Hajjar RJ, Kranias EG 2005. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1 Circ Res, 96 7, 756-766

Dostanic I, Schultz Jel J, Lorenz JN, Lingrel JB 2004. The 1 isoform of Na,K-ATPase regulates cardiac contractility and functionally interacts and co-localizes with the Na/Ca-exchanger in heart J Biol Chem, 279 52, 54053-54061

Dostanic, Iva; Schultz, Jo El J; Lorenz, John N; Lingrel, Jerry B 2004. The alpha 1 isoform of Na,K-ATPase regulates cardiac contractility and functionally interacts and co-localizes with the Na/Ca exchanger in heart. The Journal of biological chemistry, 279 52, 54053-61

Moseley AE, Cougnon MH, Grupp IL, El Schultz J, Lingrel JB 2004. Attenuation of cardiac contractility in Na,K-ATPase 1 isoform-deficient hearts under reduced calcium conditions J Mol Cell Cardiol, 37 5, 913-919

Schultz Jel J, Glascock BJ, Witt SA, Nieman ML, Nattami KJ, Liu LH, Lorenz JN, Shull GE, Kimball TR, Periasamy M 2004. Accelerated onset of heart failure during pressure overload in mice with chronically decreased SERCA2 calcium pump activity Am J Physiol, 286 , H1146-1153

Schultz, Jo El J; Glascock, Betty J; Witt, Sandra A; Nieman, Michelle L; Nattamai, Kalpana J; Liu, Lynne H; Lorenz, John N; Shull, Gary E; Kimball, Thomas R; Periasamy, Muthu 2004. Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity. American journal of physiology. Heart and circulatory physiology, 286 3, H1146-53

Azhar, Mohamad; Schultz, Jo El J; Grupp, Ingrid; Dorn, Gerald W; Meneton, Pierre; Molin, Daniel G M; Gittenberger-de Groot, Adriana C; Doetschman, Thomas 2003. Transforming growth factor beta in cardiovascular development and function. Cytokine & growth factor reviews, 14 5, 391-407

Dostanic I, Lorenz JN, Schultz Jel J, Grupp IL, Neumann JC, Lingrel JB 2003. Increase in cardiac contractility by low concentrations of ouabain is mediated through the 2 NA,K-ATPase isozyme J Biol Chem, 278 52, 53026-53034

Dostanic, Iva; Lorenz, John N; Schultz, Jo El J; Grupp, Ingrid L; Neumann, Jonathan C; Wani, Maqsood A; Lingrel, Jerry B 2003. The alpha2 isoform of Na,K-ATPase mediates ouabain-induced cardiac inotropy in mice. The Journal of biological chemistry, 278 52, 53026-34

House SL, Bolte C, Zhou M, Doetschman T, Klevitsky R, Newman G, Schultz Jel J 2003. Cardiac-specific overexpression of fibroblast growth factor-2 (FGF2) protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia Circulation, 108 , 3140-3148

Maslov LN, Lishmanov YB, Gross GJ, Schultz JE, Stefano G 2002. Opioid receptor activation alters cardiac tolerance to ischemic and reperfusion damages Vestnik Arrhythmologyi (Russian), N28 , 67-78

Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix S, Kimball TR, Doetschman T 2002. Transforming growth factor-1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II (see commentary: Schneider MD. Serial killer: angiotensin drives cardiac hypertrophy via TGF-1 J Clin Invest, 109 , 715-716

Schultz, Jo El J; Witt, Sandra A; Glascock, Betty J; Nieman, Michelle L; Reiser, Peter J; Nix, Stacey L; Kimball, Thomas R; Doetschman, Thomas 2002. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. The Journal of clinical investigation, 109 6, 787-96

Fryer R, Schultz JE, Hsu A, Gross G 1999. Importance of PKC and tyrosine kinase in single or multiple cycles of preconditioning in rat hearts Am J Physiol, 276 , H1229-H1235

Schultz JE, Witt SA, Nieman ML, Reiser PJ, Engle SJ, Zhou M, Pawlowski SA, Lorenz JN, Kimball TR, Doetschman T 1999. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response (featured on cover) J Clin Invest, 104 , 709-719

Schultz, J E; Witt, S A; Nieman, M L; Reiser, P J; Engle, S J; Zhou, M; Pawlowski, S A; Lorenz, J N; Kimball, T R; Doetschman, T 1999. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. The Journal of clinical investigation, 104 6, 709-19

Fryer RM, Schultz JE, Hsu AK, Gross GJ 1998. Pretreatment with tyrosine kinase inhibitors partially attenuates ischemic preconditioning in the rat heart Am J Physiol, 275 , H2009-H2015

Gumina RJ, Mizumura T, Beier N, Schelling P, Schultz JJ, Gross GJ 1998. A new sodium/hydrogen exchanger inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion J Pharmacol Exp Therap, 286 1, 175-183

Schultz J el-J, Hsu AK, Nagase H, Gross GJ 1998. TAN-67, a selective delta-1 (1) opioid receptor agonist, reduces myocardial infarct size via activation of Gi/o proteins and KATP channels Am J Physiol, 274 , H909-H914

Schultz JE, Hsu AK, Barbieri JT, Li P-L, Gross GJ 1998. Pertussis toxin abolishes the cardioprotective effect of ischemic preconditioning in the intact rat heart Am J Physiol, 275 , H495-H500

Schultz JE, Hsu AK, Gross GJ 1998. Ischemic preconditioning (PC) in the intact rat heart is mediated by delta1 (1), but not mu () or kappa () opioid receptors Circulation, 97 , 1282-1289

Schultz JE, Hsu AK, Kwok W-M, Gross GJ 1998. Terikalant, the inward-rectifier potassium channel blocker, does not abolish the cardioprotection induced by ischemic preconditioning in the rat J Mol Cell Cardiol, 30 , 1817-1825

Schultz JE, Qian YZ, Gross GJ, Kukreja RC 1997. The ischemia-selective KATP channel antagonist, 5-hydroxydecanoate, blocks the ischemic preconditioning in the rat heart J Mol Cell Cardiol, 29 , 1055-1060

Schultz JE, Yao Z, Cavero I, Gross GJ 1997. Glibenclamide abolishes ischemic preconditioning in a time-dependent manner in the rat heart Am J Physiol, 272 , H2607-H2615

Schultz JJ, Hsu AK, Gross GJ 1997. Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart J Mol Cell Cardiol, 29 , 1355-1362

Schultz JJ, Hsu AK, Gross GJ 1997. Ischemic preconditioning and morphine-induced cardioprotection involve the delta ()-opioid receptor in the intact rat heart J Mol Cell Cardiol, 29 , 2187-2195

Smart SC, Sagar KB, el Schultz J, Warltier DC, Jones LR 1997. Injury to the Ca2+ ATPase of the sarcoplasmic reticulum in anesthetized dogs contributes to myocardial reperfusion injury Cardiovasc Res, 36 , 174-184

Gumina RJ, el Schultz J, Yao Z, Kenny D, Warltier DC, Newman PJ, Gross GJ 1996. Antibody to Platelet/Endothelial Cell Adhesion Molecule-1 reduces myocardial infarct size in a rat model of ischemia/reperfusion injury Circulation, 94 , 3327-3333

Schultz JE, Hsu AK, Gross GJ 1996. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart Circ Res, 78 , 1100-1104

Schultz JE, Rose E, Yao Z, Gross GJ 1995. Evidence for the involvement of opioid receptors in ischemic preconditioning in the rat heart Am J Physiol, 268 , H2157-H2161

Smart SC, LoCurto A, el Schultz J, Sagar KB, Warltier DC 1995. Intracoronary amiloride prevents contractile dysfunction of postischemic “stunned” myocardium: role of hemodynamic alterations and inhibition of Na+/H+ exchange and L-type Ca2+ channels J Am Coll Cardiol, 26 5, 1365-1373

Pietras DA, Newman G, Schultz JelJ 2008. KATP channels are important downstream targets of FGF2-initiated cardioprotective signaling in mice FASEB J , ,

Carpenter G, Porter D, Liao S, Newman G, Schultz J El J 2007. Inducible nitric oxide synthase (iNOS), not neuronal NOS (nNOS) in cardioprotection by fibroblast growth factor-2 (FGF-2) J Mol Cell Cardiol , 42 , S187

Liao S, Newman G, Doetschman T, Schultz J El J 2007. Role of high molecular weight isoforms of fibroblast growth factor-2 (FGF-2) in cardiac ischemia-reperfusion injury (I/R) J Mol Cell Cardiol, 42 , S198

Ren X, Liao S, Schultz JJ, Brown M, Jones WK 2007. PKCe mediates nonischemic preconditioning-dependent bradykinin-2 receptor signaling Cardiovascular repair and regeneration: structural and molecular approaches in the cellular era, American Heart Association meeting, ,

Bolte CS, Newman G, Schultz J 2006. The role of the opioidergic system in a familial model of dilated cardiomyopathy FASEB J, 20 , C99

Porter D, House S, Newman G, Schultz JJ 2006. Evidence for a role in nitric oxide signaling in fibroblast growth factor-2-induced cardioprotection Gordon Research Conference on Fibroblast Growth Factors in Development and Disease, ,

Liao S, Porter D, Newman G, Doetschman T, Schultz JJ 2005. Cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: the role of JNK signaling Circulation, 112 17, II-252

Bolte C, Newman G, el Schultz J 2004. Evidence for the involvement of the opioidergic system in the development of heart failure J Mol Cell Cardiol, 37 1, 203

House SL, el Schultz J, Glascock B, Kimball T, Doetschman T 2004. Fibroblast growth factor 2 mediates cardiac hypertrophy induced by isoproterenol through specific MAPK and PKC pathways J Mol Cell Cardiol, 37 1, 299

House SL, Newman G, Doetschman T, Schultz JJ 2004. Role of ERK and p38 in cardioprotection induced by overexpression of fibroblast growth factor 2 in the heart J Mol Cell Cardiol, 36 , 626

Pathak A, del Monte F, Zhao W, Carr A, Schultz J, Hahn H, Syed F, Mareez Y, DePaoli-Roach A, Hajjar R, Kranias EG 2004. Therapeutic targeting of the type 1 phosphatase activity in murine models of cardiomyopathy Circulation, 110 17, I-22

Dostanic I, Lorenz J, Grupp IL, Schultz JJ, Neumann JC, Lingrel JB 2003. Inotropic effect of ouabain is mediated through the 2 Na,K-ATPase in heart FASEB J, 17 5, A1323

House SL, Newman G, Doetschman T, Schultz JJ 2003. Cardiac-specific overexpression of FGF2 is cardioprotective via a protein kinase C-dependent pathway in a murine model of global low-flow ischemia Molecular mechanisms of growth, death, and regeneration in the myocardium: basic biology and insights into ischemic heart disease and heart failure, American Heart Association meeting, ,

Liao S, Newman G, Doetschman T, Schultz JJ 2003. Evidence for the low molecular weight isoform of fibroblast growth factor-2 to protect against ischemia-reperfusion injury Molecular mechanisms of growth, death, and regeneration in the myocardium: basic biology and insights into ischemic heart disease and heart failure, American Heart Association meeting, ,

Liao S, Newman G, Doetschman T, Schultz JJ 2003. Evidence for the low molecular weight isoform of fibroblast growth factor-2 to protect against ischemia-reperfusion injury Circulation, 108 17, IV-187

Flaherty MP, Brown M, Takano H, el Schultz J, Murphree S, and Jones WK 2002. Compensated cardiac hypertrophy in eNOS knockout mice J Am Coll Cardiol, 39 5, 131A

Schultz JJ, Klevitsky R, Jakes H, Doetschman T, Newman G 2002. Cardioprotective role of FGF2 in a murine model of low-flow ischemia J Mol Cell Cardiol, 34 7, A37

Schultz JJ, Grupp IL, Millard RW 2001. Utilizing the isolated mammalian heart for evaluations of novel candidate drug beneficial and adverse events Safety Pharmacology meeting, ,

Flaherty MP, Takano H, Murphree SS, Grupp I, Schultz J, Jones WK 2000. Hypertensive-cardiac hypertrophy and induction of molecular markers in eNOS knockout mice J Mol Cell Cardiol, 32 5, A57

Schultz J, Witt SA, Glascock BJ, Lorenz J, Kimball TR, Doetschman T 2000. Transforming growth factor 1 (TGF1) in a murine model of cardiac hypertrophy J Mol Cell Cardiol, 32 5, A60

Schultz JJ, Liu LH, Witt SA, Glascock BJ, Kimball TR, Shull GE, Periasamy M 2000. Accelerated onset of heart failure during pressure overload in mice with chronically decreased SERCA2 calcium pump activity Circulation , 100 18, I52

Witt SA, Schultz JJ, Doetschman TC, Kimball TR 2000. The impact of a novel imaging transducer in the assessment of a pressure overload mouse model of cardiac hypertrophy J Am Coll Cardiol, 352 2, 472A

Witt SA, Schultz JJ, Lorenz J, Doetschman TC, Kimball TR 2000. Invasive validation of in vivo echocardiographic indices of pressure gradients in a murine model J Am Soc Echo, 13 5, 466

Witt SA, Schultz JJ, Lorenz J, Doetschman TC, Kimball TR 2000. Invasive validation of in vivo echocardiographic indices of pressure gradients in a murine model J Mol Cell Cardiol, 32 5, A37

Schultz JJ, Witt SA, Nieman M, Engle SJ, Lorenz JN, Kimball TR, Doetschman T 1999. Basic fibroblast growth factor in a pressure overload mouse model of cardiac hypertrophy Weinstein Cardiovascular Development Conference, ,

Schultz JJ, Witt SA, Nieman ML, Engle SJ, Lorenz JN, Kimball TR, Doetschman T 1999. Fibroblast growth factor-2 involvement in the hypertrophic response to pressure overload in mouse Circulation, 100 18, I-52

Schultz JJ, Witt SA, Ormsby I, Lorenz JN, Kimball TR, Doetschman T 1999. Role of TGFb1 in aspects of cardiac hypertrophy in the mouse Molecular Basis of Heart Disease Meeting, ,

Fryer R, Schultz J, Hsu A, Gross G 1998. Tyrosine kinase is involved in the initiation of ischemic preconditioning in rats FASEB J, 12 4, A77

Fryer R, Schultz J, Hsu A, Gross GJ 1998. Combined inhibition of tyrosine kinase (TK) and protein kinase C (PKC) are necessary to totally abolish ischemic preconditioning (IPC) in rat hearts Circulation, 98 17, I-585

Gross GJ, Hsu AK, Schultz JJ 1998. ATP-sensitive potassium (KATP) channels and Gi/o proteins mediate the cardioprotection afforded by delta-1 (1) opioid receptor stimulation in the intact rat FASEB Journal, 12 5, A1113

Sutliff RL, Paul RJ, Zhou M, Hoying JB, Schultz J, Doetschman T 1998. FGF2 isoform specificity in vascular tone control Weinstein Cardiovascular Development Conference, ,

Gross GJ, Mizumura T, Beier N, Schultz JJ 1997. A new Na+-H+ exchange (NHE) inhibitor, EMD 85131, limits infarct size in dogs when administered prior to or after coronary occlusion J Mol Cell Cardiol, 29 6, A196

Gross GJ, Mizumura T, Schultz JJ 1997. A new sodium-hydrogen exchange (NHE) inhibitor, EMD 85131, limits infarct size (IS) in dogs independent of adenosine (Ado) or ATP-sensitive potassium (KATP) channels Circulation, 96 8, I-140

Gross GJ, Schultz JJ 1997. In dogs tolerant to ischemic preconditioning (IPC), the sodium-hydrogen exchange (NHE) inhibitor, EMD 85131 (EMD), retains its efficacy to reduce myocardial infarct size (IS) Circulation, 96 8, I-743

Schultz JJ, Hsu AK, Gross GJ 1997. Gi/o proteins are involved in the cardioprotective effect of ischemic preconditioning (PC) in the intact rat Circulation, 96 8, I-574

Schultz JJ, Hsu AK, Nagase H, Gross GJ 1997. Ischemic preconditioning (PC) in the intact rat heart is mediated by delta1 (1), but not mu () or kappa () opioid receptors J Mol Cell Cardiol, 29 6, A200

Gross GJ, Schultz JJ 1996. Glibenclamide abolishes ischemic preconditioning in a time-dependent manner in the rat heart FASEB J, 10 3, 809

Schultz JJ, Hsu A, Gross GJ 1996. Morphine-induced cardioprotection is mediated via the ATP-sensitive potassium (KATP) channel in the rat heart FASEB J, 10 3, 68

Schultz JJ, Hsu AK, Gross GJ 1996. Delta opioid receptors appear to mediate ischemic- or morphine-induced preconditioning in the intact rat heart Circulation, 90 8, I-364

Eells JT, Flaig AM, Schultz JJ, Salzman JJ 1995. Methanol toxicity: species differences in retinal formate oxidation Society for Neuroscience Abstracts, 21 , 1741

Gumina RJ, Schultz J, Yao Z, Kenny D, Warltier DC, Gross GJ, Newman PJ 1995. Characterization of rat PECAM-1 and demonstration that antibody to PECAM-1 reduces myocardial infarct size J Invest Med, 43 Suppl 3, 451A

Schultz JJ, Yao Z, Gross GJ 1994. Evidence for the involvement of opioid receptors in ischemic preconditioning in the rat heart Circulation, 90 4, I-476

Smart SC, Schultz J, LoCurto A, Sagar KB, Warltier DC 1994. Inhibition of Na/H exchange is not the mechanism by which amiloride improves postischemic function in open chest dogs J Am Coll Cardiol (Special Issue), , 297A

Smart SC, Schultz J, LoCurto A, Sagar KB, Warltier DC 1994. High dose nifedipine, but not high dose verapamil, prevents postischemic myocardial dysfunction in open chest dogs Clin Res, 42 2, 162A

Smart SC, Schultz J, Sagar KB, Warltier DC 1993. Intracoronary doxorubicin, but not intracoronary verapamil, improves recovery of postischemic function J Am Coll Cardiol, 21 , 164A

Smart SC, Schultz J, Sagar KB, Warltier DC 1993. Vasodilation alone does not account for the improved postischemic myocardial function following treatment with intracoronary amiloride Clin Res, 41 2, 228A

Smart SC, Schultz J, Sagar KB, Warltier DC 1993. Is amiloride the vasodilator of choice for syndromes of acute ischemia and reperfusion? Clin Res, 41 3, 642A

Smart SC, Schultz J, Sagar KB, Warltier DC 1993. Doxorubicin is the calcium transport antagonist of choice for preventing reperfusion ventricular fibrillation Clin Res, 41 3, 684A